Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799195 · ClinicalTrials.gov registry record · Phase 2
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD), sponsored by University of Nebraska.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06799195: Recruiting Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD), sponsored by University of Nebraska.
NCT06799195 is a Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD) that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 126 participants, below the 769-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799195, a Phase 2 study of Hematological Malignancies and Graft-versus-host Disease (GVHD), is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Primary Outcome
The health-related quality of life will be assessed using the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) trial outcome index (TOI). The FACT-BMT is a validated, patient-reported questionnaire that measures physical and functional well-being specifically in bone marrow transplant recipients. Higher scores indicate better quality of life. The primary outcome is to compare the FACT-BMT TOI scores between the attenuated-dose PTCy arm and the high-dose PTCy arm at
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Attenuated-dose Cyclophosphamide
- DRUG High-dose Cyclophosphamide
- DRUG Mycophenolate Mofetil (MMF)
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2031-11 |
| Phase | Phase 2 |
What NCT06799195 shows while recruiting
NCT06799195 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 769-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Hematological Malignancies appearing as the primary indexed condition, and to 4 interventions - of which Sirolimus is the first listed.
NCT06799195 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT06799195 about?
NCT06799195 is a clinical study titled "Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation". This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
What is the current status of trial NCT06799195?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-06-23. Estimated completion is 2031-11.
What conditions does trial NCT06799195 study?
This clinical trial studies the following conditions: Hematological Malignancies, Graft-versus-host Disease (GVHD).
What interventions are being tested in trial NCT06799195?
The interventions under investigation include: Sirolimus (DRUG), Attenuated-dose Cyclophosphamide (DRUG), High-dose Cyclophosphamide (DRUG), Mycophenolate Mofetil (MMF) (DRUG).
Who is sponsoring clinical trial NCT06799195?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799195 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06799195's enrollment target sits among peer trials
126 8th of 16 higher than 9 of 16 other Hematological Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
COMPLETED · Phase 2
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RECRUITING
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI